Pacira achieving a favourable resolution with the FDA and confirming EXPAREL®’s broad indication is a very positive development and should remove any doubt over the product. It was also confirmed that oral surgery is covered by the approved indication and Pacira plans to launch EXPAREL® for this indication in Q4 2016. We continue to expect EXPAREL®’s growth trajectory to increase and for Skyepharma to receive an $8m sales milestone in 2016. We remain bullish on EXPAREL®’s long term growth potent ....
16 Dec 2015
Positive development with EXPAREL®
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive development with EXPAREL®
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
16 Dec 2015 -
Author:
Sheena Berry -
Pages:
3
Pacira achieving a favourable resolution with the FDA and confirming EXPAREL®’s broad indication is a very positive development and should remove any doubt over the product. It was also confirmed that oral surgery is covered by the approved indication and Pacira plans to launch EXPAREL® for this indication in Q4 2016. We continue to expect EXPAREL®’s growth trajectory to increase and for Skyepharma to receive an $8m sales milestone in 2016. We remain bullish on EXPAREL®’s long term growth potent ....